- Home
- SILO vs KTTA Comparison
SILO vs KTTA Comparison
Compare SILO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- KTTA
- Stock Information
- Founded
- SILO 2010
- KTTA 2020
- Country
- SILO United States
- KTTA United States
- Employees
- SILO N/A
- KTTA N/A
- Industry
- SILO Apparel
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- KTTA Health Care
- Exchange
- SILO Nasdaq
- KTTA Nasdaq
- Market Cap
- SILO 3.1M
- KTTA 2.8M
- IPO Year
- SILO N/A
- KTTA 2021
- Fundamental
- Price
- SILO $0.58
- KTTA $0.89
- Analyst Decision
- SILO
- KTTA
- Analyst Count
- SILO 0
- KTTA 0
- Target Price
- SILO N/A
- KTTA N/A
- AVG Volume (30 Days)
- SILO 2.4M
- KTTA 2.3M
- Earning Date
- SILO 05-09-2025
- KTTA 05-15-2025
- Dividend Yield
- SILO N/A
- KTTA N/A
- EPS Growth
- SILO N/A
- KTTA N/A
- EPS
- SILO N/A
- KTTA N/A
- Revenue
- SILO $72,102.00
- KTTA N/A
- Revenue This Year
- SILO $1.86
- KTTA N/A
- Revenue Next Year
- SILO N/A
- KTTA N/A
- P/E Ratio
- SILO N/A
- KTTA N/A
- Revenue Growth
- SILO N/A
- KTTA N/A
- 52 Week Low
- SILO $0.41
- KTTA $0.79
- 52 Week High
- SILO $4.50
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- SILO 45.16
- KTTA 38.94
- Support Level
- SILO $0.43
- KTTA $0.87
- Resistance Level
- SILO $0.49
- KTTA $0.95
- Average True Range (ATR)
- SILO 0.06
- KTTA 0.07
- MACD
- SILO 0.03
- KTTA 0.01
- Stochastic Oscillator
- SILO 45.03
- KTTA 40.41
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).